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Background
PD-1/PD-L1 immune checkpoint pathway mediates
tumor evasion from the immune system, and may be
associated with poor prognosis in lung cancer. Activat-
ing KRAS mutations and LKB1 loss are common muta-
tions in non-small cell lung carcinoma (NSCLC).
Patients with mutated KRAS demonstrate less benefit
from chemotherapy and resistance to approved targeted
therapies. Inactivation of tumor suppressors commonly
co-exist with KRAS mutations, and may contribute to
tumor progression and treatment response. LKB1 is a
tumor suppressor gene commonly inactivated in lung
adenocarcinomas. The role of LKB1loss as a prognostic
or predictive marker within human KRAS mutant
NSCLC is unclear. There have been no therapeutic stra-
tegies that effectively target LKB1. Furthermore, the
effect of these mutations on immune checkpoint immune
regulation is poorly understood. KRAS mutations are
known to activate the RAF-MEK-ERK pathway. We
hypothesize that KRAS mutations directly regulate the
PD-1/PD-L1 pathway and LKB1 loss may increase this
effect through ERK activation.
Methods
Immortalized human bronchial epithelial cells (HBEC) with
null vector and shRNA control (HBEC-vector-sh control),
HBEC LKB1 knockdown (HBEC-vector-shLKB1), KRAS–
mutated (KRASv12) HBEC cells with shRNA control
(HBEC-KRAS-sh control), and LKB1 knockdown KRAS–
mutated HBEC cells (HBEC-KRAS-shLKB1) were used to
assess mRNA and/or surface protein expression levels of
PD-L1 by real time-qPCR (RT-qPCR) and flow cytometry.
HBEC-vector and HBEC-KRAS cells were treated with
MEK (ERK kinase) inhibitor (PD0325901) at 1uM for
24hrs and evaluated for mRNA and surface protein expres-
sion of PD-L1.
Results
PD-L1 mRNA level increased 2.4 fold (HBEC-KRAS-sh
control; p < 0.05) and 4 fold (HBEC-KRAS-shLKB1; p <
0.05) vs. HBEC-vector-sh control. Based on mean fluores-
cence intensity, PD-L1 protein expression was 7.4 (HBEC-
KRAS-sh control) and 12.1 (HBEC-KRAS-shLKB1) vs.
3.4 (HBEC-vector-sh control). With ERK inhibition, PD-L1
mRNA levels decreased 88% (HBEC-KRAS-sh control) and
68% (HBEC-KRAS-shLKB1), and PD-L1 surface protein
levels were reduced 77% (HBEC-KRAS-sh control) and
64% (HBEC-KRAS-shLKB1). These findings suggest that
ERK activation mediates KRAS mutation driven over-
expression of PD-L1 mRNA and protein, which is further
increased with LKB1 loss. LKB1 loss alone without KRAS
mutation did not significantly affect PD-L1 expression
(HBEC-vector-shLKB1 vs. HBEC-vector-sh control).
Conclusions
Here, we demonstrate that elevated PD-L1 expression
in premalignant KRAS mutated human bronchial
epithelial cells is enhanced by LKB1 loss and mediated1UCLA, Los Angeles, CA, USA
Full list of author information is available at the end of the article
Lee et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P305
http://www.immunotherapyofcancer.org/content/3/S2/P305
© 2015 Lee et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
by MAPK/ERK pathway activation. Our findings suggest
that activating KRAS mutations and LKB1 loss in NSCLC
may predict improved therapeutic efficacy to PD-1/PD-L1
inhibition.
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